Alaunos Therapeutics: Nasdaq confirms regained compliance, listing to continue

What happened Alaunos Therapeutics reported that on Oct 22, 2026 Nasdaq’s Office of General Counsel advised the Company that the Listing Qualifications Department (the “Staff”) has confirmed the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the $2,500,000 stockholders’ equity requirement). The Company said it received earlier notices of non-compliance on Apr 9, 2026 and a delisting notice on Oct 5, 2026, and had timely requested a hearing before the Nasdaq Hearings Panel scheduled for Nov 10, 2026. The Company previously reported that completion of a private placement on Oct 14, 2026 led it to believe it had regained compliance; Nasdaq’s Oct 22, 2026 letter closed the matter, cancelled the Nov 10, 2026 hearing, and stated the Company’s common stock will continue to be listed and traded on The Nasdaq Capital Market.

Key details

• Nasdaq Listing Rule involved: 5550(b)(1), minimum stockholders’ equity of $2,500,000.
• Apr 9, 2026: initial written notice of non-compliance from Nasdaq’s Listing Qualifications Department.
• Oct 5, 2026: written delisting notice issued; hearing requested and scheduled for Nov 10, 2026.
• Oct 14, 2026: closing of private placement that the Company said restored compliance; Oct 22, 2026: Nasdaq confirmed compliance and cancelled the hearing.

Why it may matter This filing is Item 8.01 (other events) and covers Nasdaq listing compliance actions, notices received from Nasdaq, the Company’s private placement that it said restored compliance, and Nasdaq’s subsequent confirmation that the Company has regained compliance and that its common stock will continue to be listed and traded. A filing does not show why the insider traded or why the company acted.